Towards Healthcare
Advanced Therapy Medicinal Products CDMO Market Booms at 18.82% CAGR

Advanced Therapy Medicinal Products CDMO Market Surges with Biotech Startup Demand and Clinical iPSC Bank Launches in 2025

Based on market forecasts, the global advanced therapy medicinal products CDMO market, projected at USD 6.73 billion in 2024, is expected to reach USD 37.27 billion by 2034, growing at a CAGR of 18.82% over the forecast period. The global market is driven by an increase in the pipeline of ATMP candidates in clinical trials, necessary the growth of strong production facilities. In this market, North America dominated the market due to the growing cases of major diseases like cancer, genetic conditions, and neurological diseases, and major investments in cell and gene therapy R&D.

Content

  • Insight Code: 5868
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The advanced therapy medicinal products CDMO market is projected to reach USD 37.27 billion by 2034, growing at a CAGR of 18.82% from 2024 to 2034.

North America is currently leading the advanced therapy medicinal products CDMO market due to rising cases of major diseases like cancer, genetic conditions, and neurological diseases, and major investments in cell and gene therapy R&D.

The advanced therapy medicinal products CDMO market includes seven segments, such as by product type, by vector type, by workflow stage, by end use/application, by client type, by cell type, and by region, etc.

Some key players include AGC Biologics, Aldevron, Andelyn Biosciences, BlueReg, and Brammer Bio (Thermo Fisher Scientific).

Key trends include rising demand for personalized medicine and therapies, growth in technological advancements, and innovation in clinical trials, manufacturing facilities.

ATMP CDMOs provide a range of services, including process development, analytical testing, manufacturing, and regulatory support, to help pharmaceutical companies introduce ATMP products to market. 

Some key considerations when choosing an ATMP CDMO are expertise and experience, specialized facilities, quality and regulatory compliance, and project management and communication.

There are three main categories of ATMPs are gene therapy medicinal products, cell therapy medicinal products, and tissue engineering products.

NIH.GOV, CDC.GOV, US FDA, EMA, ATMP SWEDEN, AIFA.GOV, ABPI, GOV.UK
Any Questions